Upadacitinib

Last updated

Upadacitinib
Upadacitinib.svg
Clinical data
Pronunciation /juˌpædəˈsɪtɪnɪb/
ew-PAD-ə-SI-ti-nib
Trade names Rinvoq
Other namesABT-494
AHFS/Drugs.com Monograph
MedlinePlus a619051
License data
Pregnancy
category
  • AU:D
  • Not recommended [1]
Routes of
administration 		By mouth
Drug class Janus kinase (JAK) inhibitor
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding 52%
Metabolism Liver (CYP3A major, CYP2D6 minor) [12]
Metabolites M4, an acyl glucuronide
Elimination half-life 9–14 [13] (6–15 [12] ) hours
Excretion Mainly unchanged in feces (38%) and urine (24%) [13]
Identifiers
  • (3S,4R)-3-Ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C17H19F3N6O
Molar mass 380.375 g·mol−1
3D model (JSmol)
  • CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
  • InChI=1S/C17H19F3N6O/c1-2-10-7-25(16(27)24-9-17(18,19)20)8-11(10)13-5-22-14-6-23-15-12(26(13)14)3-4-21-15/h3-6,10-11,21H,2,7-9H2,1H3,(H,24,27)/t10-,11+/m1/s1 Yes check.svgY
  • Key:WYQFJHHDOKWSHR-MNOVXSKESA-N Yes check.svgY

Upadacitinib, sold under the brand name Rinvoq, is a medication used for the treatment of rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn's disease, ankylosing spondylitis, and axial spondyloarthritis. [10] [11] Upadacitinib is a Janus kinase (JAK) inhibitor that works by blocking the action of enzymes called Janus kinases. [10] [14] [11] These enzymes are involved in setting up processes that lead to inflammation, and blocking their effect brings inflammation in the joints under control. [11]

Contents

Common side effects include upper respiratory tract infections (common cold, sinus infections), nausea, cough, and fever. [10] [11]

Upadacitinib was approved for medical use in both the United States and the European Union in 2019. [11] [14] [15] [16]

Medical uses

Upadacitinib is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn's disease, ankylosing spondylitis, and axial spondyloarthritis. [10]

Upadacitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (DMARDs). [11] Upadacitinib may be used as monotherapy or in combination with methotrexate. [10] [11]

Upadacitinib was approved in January 2022, by the FDA for treating adults and children twelve years of age and older with moderate to severe treatment refractory atopic dermatitis. [10] [17]

Upadacitinib was approved in March 2022, by the FDA for treating adults with moderately to severely active ulcerative colitis who did not respond to treatment with anti-TNF drugs (e.g. infliximab). [18]

Upadacitinib was approved in February 2023, by the UK Medicines and Healthcare products Regulatory Agency (MHRA) to treat adults with moderately to severely active Crohn's disease. [19] [20]

In April 2023, upadacitinib was approved in the EU for the treatment of moderately to severely active Crohn's disease in adults. [21] [22] [23]

In May 2023, the FDA approved upadacitinib for the treatment of adults with moderately to severely active Crohn's disease who have had an inadequate response or intolerance to one or more TNF blockers. [10] [24] [25]

Contraindications

The US Food and Drug Administration (FDA) requires a boxed warning for tofacitinib, baricitinib, and upadacitinib to include information about the risks of serious heart-related events, cancer, blood clots, and death. [26] [27]

The drug is contraindicated in people with active tuberculosis and other severe infections, severe liver impairment (Child–Pugh score  C), and during pregnancy. [13] [28]

Interactions

Substances that strongly inhibit the liver enzyme CYP3A4, such as ketoconazole, itraconazole, or clarithromycin, increase upadacitinib concentrations in the body. In a study, ketoconazole increased its AUC by 75%. Conversely, substances that strongly induce CYP3A4 lower upadacitinib concentrations. For example, rifampicin reduced the AUC by 60% in a study. [13] [28]

Upadacitinib seems to be a weak inducer of CYP3A4, as it lowers concentrations of other substrates of this enzyme (such as the midazolam AUC by 26%). It has no effect on substrates of CYP1A2, CYP2B6, CYP2C9, CYP2C19, or CYP2D6. [13] [28]

Side effects

Common side effects include upper respiratory tract infections such as common cold and sinus infections, nausea, cough, and fever. [10] [11]

Pharmacology

Mechanism of action

The Janus kinases (JAKs) are a family of cytoplasmic tyrosine kinases whose function is to transduce cytokine-mediated signals via the JAK-STAT pathway. There are four JAK subtypes, each of which has overlapping receptor responsibilities. Inhibitors of this enzyme family (jakinibs) have shown efficacy in treating certain inflammatory and autoimmune diseases such as rheumatoid arthritis and Crohn's disease. However, the first generation of these drugs, tofacitinib and ruxolitinib, lacked subtype selectivity, affecting JAK1/JAK3 and JAK1/JAK2 respectively. This has led to dose-limiting side effects in this otherwise promising class of drugs. [29] [30] Upadacitinib is a second generation Janus kinase inhibitor that is selective for the JAK1 subtype of this enzyme over the JAK2 (74-fold), JAK3 (58-fold) and tyrosine kinase 2 subtypes. [31]

Pharmacokinetics

After oral intake, upadacitinib reaches highest concentrations in the blood plasma after two to four hours. A fatty meal has no clinically relevant effect on its resorption. Steady-state conditions are reached after four days; accumulation is minimal. There is no significant first pass effect. When in the bloodstream, 52% of the substance are bound to plasma proteins. It is mainly metabolized by CYP3A4, and possibly to a minor extent by CYP2D6. The most important pathway consists of oxidation to a carboxylic acid and subsequent glucuronidation, yielding a metabolite called M4. However, 79% of the drug circulates in the form of upadacitinib itself, and only 13% as M4. Other metabolites are only present in small fractions. None are pharmacologically active. [13] [28]

The drug is excreted mainly as the original substance, of which 38% are found in the feces and 24% in the urine. The mean terminal half-life is 9 to 14 hours. [13] [28]

History

Upadacitinib was approved for medical use in the United States in August 2019. [15] [14]

The US Food and Drug Administration (FDA) approved upadacitinib based on evidence from five clinical trials (Trial 1/NCT02706873, Trial 2/NCT02706951, Trial 3/NCT02675426, Trial 4/NCT02629159, Trial 5/NCT02706847) of 3,141 participants with active rheumatoid arthritis (RA). [14] The trials were conducted in Australia, New Zealand, Israel, South Africa, Asia, North/Central/South America, and Europe. [14]

Five trials established the benefits and side effects of upadacitinib. [14] Trials enrolled participants with moderate to severe active RA in whom disease-modifying antirheumatic drugs did not work well or could not be tolerated. [14] All participants had at least six tender and six swollen joints, and increased levels of high sensitivity C-reactive protein (hsCRP). [14] hsCRP is a substance produced by the body to protect itself from illness. [14] Trials lasted up to 5 years. [14]

Trial 1 enrolled participants who had never been treated with methotrexate. [14] Participants were randomly assigned to receive one of two doses of upadacitinib or methotrexate daily for 24 weeks. [14] Neither the subject nor the healthcare providers knew which medication was being given until after this 24-week treatment period. [14]

Trial 2 enrolled participants in whom methotrexate did not work well. [14] Participants were randomly assigned to receive one of two doses of upadacitinib daily by mouth or continue their usual dose of methotrexate for 14 weeks. [14] At week 14, participants who were assigned to methotrexate received upadacitinib by mouth daily. [14] Neither the subject nor the healthcare providers knew which medication was being given. [14]

Trial 3 enrolled participants in whom disease-modifying antirheumatic drugs did not work well. [14] Participants were randomly assigned to receive one of two doses of upadacitinib or placebo daily by mouth in addition to disease-modifying antirheumatic drugs for 12 weeks. [14] At week 12, participants who received placebo were reassigned to upadacitinib daily. [14] Neither the subject nor the healthcare providers knew which medication was being given. [14]

Trial 4 enrolled participants in whom methotrexate did not work well. [14] Participants were randomly assigned to receive upadacitinib or placebo daily by mouth in addition to methotrexate for 14 weeks. [14] Participants receiving placebo who did not have adequate improvement of signs and/or symptoms could be switched to upadacitinib after week 14. [14] At week 26, all participants receiving placebo were switched to upadacitinib once daily by mouth. [14] Neither the subject nor the healthcare providers knew which medication was being given. [14]

Trial 5 enrolled participants in whom disease-modifying antirheumatic drugs did not work well or could not be tolerated. [14] Participants were randomly assigned to receive one of two doses of upadacitinib or placebo treatment daily added to disease-modifying antirheumatic drugs for 12 weeks. [14] At week 12, participants who received placebo were reassigned to upadacitinib daily. [14]

The benefit of upadacitinib was measured by comparing the proportion of participants treated with upadacitinib who achieved an American College of Rheumatology 20 (ACR20) response at week 12 or week 14 to the proportion of participants treated with MTX or placebo who achieved an ACR20 response. [14] ACR20 is a 20% improvement in signs and symptoms of RA. [14]

Upadacitinib was approved for medical use in the European Union in December 2019. [11]

In February 2023, upadacitinib was approved in the UK for treatment of Crohn's disease. [19] [20]

In April 2023, upadacitinib was approved in the EU for the treatment of moderately to severely active Crohn's disease in adults. [21] [22] The approval was for adults who "had an inadequate response, lost response, or were intolerant to conventional therapy or a biological agent". [32] [33]

The efficacy and safety of upadacitinib were evaluated in two randomized induction trials of 857 participants with moderately to severely active Crohn's disease, CD-1 (NCT03345836) and CD-2 (NCT03345849). [24] Participants were randomized 2:1 to receive 45 mg of upadacitinib or placebo once a day for 12 weeks. [24] At week 12, a greater proportion of participants treated with 45 mg of upadacitinib, as compared to placebo, achieved clinical remission based on the Crohn's Disease Activity Index (CDAI), which measures clinical and laboratory variables that estimate disease activity in Crohn's disease. [24] Similarly, a greater proportion of participants treated with 45 mg of upadacitinib demonstrated improvement in intestinal inflammation as assessed by colonoscopy. [24]

To assess upadacitinib as a maintenance treatment, CD-3 (NCT03345823) evaluated 343 participants who responded to 12 weeks of 45 mg of upadacitinib once daily. [24] Participants were re-randomized to receive a maintenance regimen of 15 or 30 mg of upadacitinib once daily or placebo for 52 weeks, representing a total of at least 64 weeks of therapy. [24] At week 52, a greater proportion of participants treated with 15 mg or 30 mg of upadacitinib, as compared to placebo, achieved clinical remission based on the CDAI, and demonstrated improvement in intestinal inflammation as assessed by colonoscopy. [24]

Clinical trials

The safety and efficacy of upadacitinib were evaluated in multiple clinical trials: [10]

Phase I studies

A phase I study revealed that upadacitinib followed a bi-exponential disposition with a terminal half-life of 6–16 hours. [12] There was no significant accumulation over the dose range of 3–36 mg per day. No interaction was found in rheumatoid arthritis participants taking methotrexate. The most common adverse event was headache but its incidence was similar to that when taking placebo (15.6% for upadacitinib vs. 16.7% for placebo). An investigation into absorption and metabolism found that dosing after a high-fat meal had no effect on upadacitinib total drug exposure over time (area under the curve or AUC). [34]

Phase II studies

Two phase IIb studies were initiated to study the efficacy and safety of upadacitinib in participants with rheumatoid arthritis and one phase II study was initiated in participants with Crohn's disease.

BALANCE I

In the first study, 276 rheumatoid arthritis participants were recruited who had previously experienced inadequate response to anti–tumor necrosis factor (TNF) therapy and were currently on a stable dose of methotrexate. [35] Participants were randomized to receive 3, 6, 12, or 18 mg twice daily or placebo. The primary endpoint was a 20% improvement in symptoms according to the American College of Rheumatology improvement criteria (ACR20). At the completion of the study it was found that response rates were significantly higher in those receiving upadacitinib versus in those receiving placebo alone (36–42% and 22– 26%, respectively). Adverse events included headache, nausea, and infection but no infections were serious.

BALANCE II

In the second phase IIb study, 300 rheumatoid arthritis participants were recruited who have had an inadequate response to methotrexate. [36] Participants were randomized to receive 3, 6, 12, or 18 mg twice daily or placebo. The primary endpoint was a 20% improvement in symptoms according to the American College of Rheumatology improvement criteria (ACR20). At the completion of the study it was found that response rates were significantly higher in those receiving upadacitinib versus in those receiving placebo alone. (62%, 68%, 80%, 64%, and 76% for the 3, 6, 12, 18, and 24 mg doses, respectively) than with placebo (46%). Improvement in symptoms was rapid, with significant changes in disease scores by week 2. Adverse events were mild with infection being the most serious. One case of community-acquired pneumonia occurred at 12 mg.

CELEST

[ needs update ] In this 16-week study, 220 participants were recruited with moderately to severely active Crohn's disease. Participants must have also experienced an inadequate response to or intolerance to Immunotherapy or TNF inhibitors. [37] [38] Participants were randomized to therapy with upadacitinib at 3, 6, 12, 24 mg twice daily or 24 mg once daily for 16 weeks or placebo, followed by blinded extension therapy for 36 weeks. The co-primary endpoints were the proportion of participants who achieved clinical remission (soft stool frequency or daily abdominal pain score) at week 16 and endoscopic remission at week 12 or 16. Secondary endpoints included significant clinical response (≥30% reduction in symptoms) at week 16 and endoscopic response (≥25% decrease in symptoms) at week 12 or 16. At 16 weeks 22% of participants taking the 24 mg twice daily dose achieved endoscopic remission with upadacitinib compared to 0% of participants taking placebo. 27% of participants taking the 6 mg twice daily dose achieved clinical remission compared to 11% of participants taking placebo. Adverse events did not appear to be dose-related. A single case of non-melanoma skin cancer was reported in the 24 mg twice daily group.

Phase III studies

Abbvie has planned a total of six phase III trials that will evaluate over 4,000 participants with moderate to severe rheumatoid arthritis. [39] Two Phase III trials are planned studying participants with psoriatic arthritis and one in participants with ulcerative colitis.

SELECT-COMPARE

In SELECT-COMPARE 1629 participants with moderate to severe rheumatoid arthritis and inadequate response to methotrexate were randomized (2:2:1) to once-daily upadacitinib 15mg, placebo, or adalimumab 40mg, on stable background methotrexate. Primary endpoints were ACR20 and DAS28CRP<2.6 versus placebo at week 12; inhibition of radiographic progression was evaluated at week 26. The study was designed and powered to test for non-inferiority and superiority of upadacitinib versus adalimumab clinically and functionally. At week 12, both primary endpoints were met for upadacitinib versus placebo (p≤0.001). ACR20 was achieved by 71% versus 36%, and DAS28CRP<2.6 by 29% versus 6%. Upadacitinib was superior to adalimumab for ACR50, DAS28CRP≤3.2, ΔPain and ΔHAQDI. At week 26, more participants on upadacitinib vs placebo or adalimumab achieved low disease activity or remission (p≤0.001). Radiographic progression was less and observed in fewer participants receiving upadacitinib versus placebo (p≤0.001). Up to week 26, adverse events (AEs) including serious infections were comparable for upadacitinib and adalimumab. The proportions of participants with serious AEs and AEs leading to discontinuation were highest for adalimumab; the proportion with herpes zoster and CPK elevations was highest for upadacitinib. Three malignancies, five MACE, and four deaths were reported, none on upadacitinib. Six venous thromboembolic events were reported [placebo, one; upadacitinib, two; adalimumab, three]. Upadacitinib was superior to placebo and adalimumab for improving signs, symptoms and physical function in RA participants on background methotrexate, and significantly inhibited radiographic progression versus placebo, while the overall safety profile was generally similar to adalimumab, except for higher rates of herpes zoster and CPK elevations on upadacitinib. [40]

SELECT-CHOICE

SELECT-CHOICE was a phase III trial comparing upadacitinib and abatacept in 612 people whose rheumatoid arthritis did not respond to biologic disease-modifying antirheumatic drugs. It compared their ability to reduce Disease Activity Score-28 with CRP (DAS-28 CRP), a measure of rheumatoid arthritis disease severity that includes number of tender and swollen joints, C-reactive protein level (a marker of inflammation), and overall health reported on a standardized scale. The trial found that after 12 weeks of treatment, people treated with upadacitinib had lower DAS-28 CRP scores and a higher rate of remission. There was also a higher rate of serious and opportunistic infections, elevated liver enzymes, and thromboembolism in the upadacitinib group. [41] [42]

Related Research Articles

<span class="mw-page-title-main">Methotrexate</span> Chemotherapy and immunosuppressant medication

Methotrexate, formerly known as amethopterin, is a chemotherapy agent and immune-system suppressant. It is used to treat cancer, autoimmune diseases, and ectopic pregnancies. Types of cancers it is used for include breast cancer, leukemia, lung cancer, lymphoma, gestational trophoblastic disease, and osteosarcoma. Types of autoimmune diseases it is used for include psoriasis, rheumatoid arthritis, and Crohn's disease. It can be given by mouth or by injection.

<span class="mw-page-title-main">Infliximab</span> Biopharmaceutical drug for autoimmune disorders

Infliximab, a chimeric monoclonal antibody, sold under the brand name Remicade among others, is a medication used to treat a number of autoimmune diseases. This includes Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, and Behçet's disease. It is given by slow injection into a vein, typically at six- to eight-week intervals.

<span class="mw-page-title-main">Disease-modifying antirheumatic drug</span> Category of drugs

Disease-modifying antirheumatic drugs (DMARDs) comprise a category of otherwise unrelated disease-modifying drugs defined by their use in rheumatoid arthritis to slow down disease progression. The term is often used in contrast to nonsteroidal anti-inflammatory drugs and steroids.

Adalimumab, sold under the brand name Humira and others, is a disease-modifying antirheumatic drug and monoclonal antibody used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis. It is administered by subcutaneous injection. It works by inactivating tumor necrosis factor-alpha (TNFα).

<span class="mw-page-title-main">Leflunomide</span> Chemical compound

Leflunomide, sold under the brand name Arava among others, is an immunosuppressive disease-modifying antirheumatic drug (DMARD), used in active moderate-to-severe rheumatoid arthritis and psoriatic arthritis. It is a pyrimidine synthesis inhibitor that works by inhibiting dihydroorotate dehydrogenase.

A TNF inhibitor is a pharmaceutical drug that suppresses the physiologic response to tumor necrosis factor (TNF), which is part of the inflammatory response. TNF is involved in autoimmune and immune-mediated disorders such as rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, psoriasis, hidradenitis suppurativa and refractory asthma, so TNF inhibitors may be used in their treatment. The important side effects of TNF inhibitors include lymphomas, infections, congestive heart failure, demyelinating disease, a lupus-like syndrome, induction of auto-antibodies, injection site reactions, and systemic side effects.

<span class="mw-page-title-main">Golimumab</span> Pharmaceutical drug

Golimumab, sold under the brand name Simponi, is a human monoclonal antibody which is used as an immunosuppressive medication. Golimumab targets tumor necrosis factor alpha (TNF-alpha), a pro-inflammatory molecule and hence is a TNF inhibitor. Profound reduction in C-reactive protein (CRP) levels, interleukin (IL)-6, intercellaular adhesion molecules (ICAM)-1, matrix metalloproteinase (MMP)-3, and vascular endothelial growth factor (VEGF) demonstrates golimumab as an effective modulator of inflammatory markers and bone metabolism. Golimumab is given via subcutaneous injection.

Tocilizumab, sold under the brand name Actemra among others, is an immunosuppressive drug, used for the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, giant cell arteritis, cytokine release syndrome, COVID‑19, and systemic sclerosis-associated interstitial lung disease (SSc-ILD). It is a humanized monoclonal antibody against the interleukin-6 receptor (IL-6R). Interleukin 6 (IL-6) is a cytokine that plays an important role in immune response and is implicated in the pathogenesis of many diseases, such as autoimmune diseases, multiple myeloma and prostate cancer. Tocilizumab was jointly developed by Osaka University and Chugai, and was licensed in 2003 by Hoffmann-La Roche.

Briakinumab (ABT-874) is a human monoclonal antibody being developed by Abbott Laboratories for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe.

A Janus kinase inhibitor, also known as JAK inhibitor or jakinib, is a type of immune modulating medication, which inhibits the activity of one or more of the Janus kinase family of enzymes, thereby interfering with the JAK-STAT signaling pathway in lymphocytes.

<span class="mw-page-title-main">Tofacitinib</span> Medication

Tofacitinib, sold under the brand Xeljanz among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, polyarticular course juvenile idiopathic arthritis, and ulcerative colitis. It is a janus kinase (JAK) inhibitor, discovered and developed by the National Institutes of Health and Pfizer.

<span class="mw-page-title-main">Fostamatinib</span> Chemical compound

Fostamatinib, sold under the brand names Tavalisse and Tavlesse, is a tyrosine kinase inhibitor medication for the treatment of chronic immune thrombocytopenia (ITP). The drug is administered by mouth.

Sarilumab, sold under the brand name Kevzara, is a human monoclonal antibody medication against the interleukin-6 receptor. Regeneron Pharmaceuticals and Sanofi developed the drug for the treatment of rheumatoid arthritis (RA), for which it received US FDA approval on 22 May 2017 and European Medicines Agency approval on 23 June 2017.

Namilumab is a human monoclonal antibody that targets granulocyte macrophage-colony stimulating factor (GM-CSF)/colony stimulating factor 2 (CSF2) and is currently being researched for application in rheumatoid arthritis (RA) and psoriatic arthritis. Clinical trials investigating the therapeutic utility of Namilumab have include phase I and phase II clinical trials to establish the safety, tolerability and preliminary therapeutic utility of the antibody in plaque psoriasis and rheumatoid arthritis.

Olokizumab (OKZ) sold under the name Artlegia, is an immunosuppressive drug, used for the treatment of rheumatoid arthritis and COVID-19. It is a humanized monoclonal antibody against the interleukin-6 (IL-6). IL-6 is a cytokine that plays an important role in immune response and is implicated in the pathogenesis of many diseases. Olokizumab is the first interleukin-6 (IL-6) inhibitor approved for treatment of rheumatoid arthritis which blocks directly cytokine instead of its receptor. Olokizumab specifically binds to IL-6 at Site 3, blocking IL-6 ability to form hexameric complex. Olokizumab was developed by R-Pharm group, and was launched in 2020.

<span class="mw-page-title-main">Baricitinib</span> Chemical compound

Baricitinib, sold under the brand name Olumiant among others, is an immunomodulatory medication used for the treatment of rheumatoid arthritis, alopecia areata, and COVID-19. It acts as an inhibitor of janus kinase (JAK), blocking the subtypes JAK1 and JAK2.

Guselkumab, sold under the brand name Tremfya, is a monoclonal antibody against interleukin-23 used for the treatment of plaque psoriasis, psoriatic arthritis, and ulcerative colitis.

<span class="mw-page-title-main">Filgotinib</span> Chemical compound

Filgotinib, sold under the brand name Jyseleca, is a medication used for the treatment of rheumatoid arthritis (RA). It was developed by the Belgian-Dutch biotech company Galapagos NV.

Risankizumab, sold under the brand name Skyrizi, is a humanized monoclonal antibody used for the treatment of plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. It is designed to target interleukin 23A (IL-23A). It is given by subcutaneous injection.

<span class="mw-page-title-main">Antiarthritics</span> Drug class

An antiarthritic is any drug used to relieve or prevent arthritic symptoms, such as joint pain or joint stiffness. Depending on the antiarthritic drug class, it is used for managing pain, reducing inflammation or acting as an immunosuppressant. These drugs are typically given orally, topically or through administration by injection. The choice of antiarthritic medication is often determined by the nature of arthritis, the severity of symptoms as well as other factors, such as the tolerability of side effects.

References

  1. ↑ "Upadacitinib (Rinvoq) Use During Pregnancy". Drugs.com. 23 September 2019. Archived from the original on 18 March 2020. Retrieved 17 March 2020.
  2. ↑ "AusPAR: Upadacitinib". Therapeutic Goods Administration (TGA). 25 August 2021. Archived from the original on 4 September 2021. Retrieved 4 September 2021.
  3. ↑ "Rinvoq (Abbvie Pty Ltd)". Archived from the original on 9 November 2022. Retrieved 9 November 2022.
  4. ↑ "Rinvoq (Abbvie Pty Ltd)". Therapeutic Goods Administration (TGA). 16 February 2023. Archived from the original on 18 March 2023. Retrieved 9 April 2023.
  5. ↑ "Rinvoq Product information". Health Canada. 25 April 2012. Archived from the original on 30 May 2022. Retrieved 29 May 2022.
  6. ↑ "Summary Basis of Decision (SBD) for Rinvoq". Health Canada. 23 October 2014. Archived from the original on 31 May 2022. Retrieved 29 May 2022.
  7. ↑ "Regulatory Decision Summary for Rinvoq". Drug and Health Products Portal. 21 July 2023. Retrieved 1 April 2024.
  8. ↑ "Rinvoq 15 mg prolonged-release tablets - Summary of Product Characteristics (SmPC)". (emc). 1 March 2020. Archived from the original on 27 August 2021. Retrieved 22 August 2020.
  9. ↑ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA . Retrieved 22 October 2023.
  10. 1 2 3 4 5 6 7 8 9 10 "Rinvoq- upadacitinib tablet, extended release". DailyMed. 1 March 2020. Archived from the original on 27 August 2021. Retrieved 29 April 2020.
  11. 1 2 3 4 5 6 7 8 9 10 "Rinvoq EPAR". European Medicines Agency (EMA). 16 October 2019. Archived from the original on 20 October 2020. Retrieved 29 April 2020.
  12. 1 2 3 Mohamed MF, Camp HS, Jiang P, Padley RJ, Asatryan A, Othman AA (December 2016). "Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Participants with Rheumatoid Arthritis". Clinical Pharmacokinetics. 55 (12): 1547–1558. doi:10.1007/s40262-016-0419-y. PMID   27272171. S2CID   39036534.
  13. 1 2 3 4 5 6 7 "Rinvoq: EPAR – Public assessment report" (PDF). European Medicines Agency. 5 March 2020. Archived (PDF) from the original on 21 July 2020. Retrieved 21 July 2020.
  14. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 "Drug Trials Snapshots: Rinvoq". U.S. Food and Drug Administration (FDA). 16 August 2019. Archived from the original on 5 August 2020. Retrieved 18 March 2020.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  15. 1 2 "Drug Approval Package: Rinvoq". U.S. Food and Drug Administration (FDA). 12 September 2019. Archived from the original on 30 March 2021. Retrieved 29 April 2020.
  16. ↑ "AbbVie Receives FDA Approval of Rinvoq (upadacitinib), an Oral JAK Inhibitor for the Treatment of Moderate to Severe Rheumatoid Arthritis" (Press release). AbbVie. Archived from the original on 16 August 2019. Retrieved 16 August 2019.
  17. ↑ "Advancing Health Through Innovation: New Drug Therapy Approvals". U.S. Food and Drug Administration (FDA). 10 January 2023. Archived from the original on 21 January 2023. Retrieved 10 February 2023.
  18. ↑ "Rinvoq (upadacitinib) Receives FDA Approval for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis" (Press release). AbbVie. Archived from the original on 7 February 2023. Retrieved 7 February 2023.
  19. 1 2 "MHRA approves first oral advanced therapy for Crohn's disease". European Pharmaceutical Review. Archived from the original on 9 February 2023. Retrieved 9 February 2023.
  20. 1 2 Cornall J (3 February 2023). "UK approval for AbbVie Crohn's disease drug". Labiotech.eu. Archived from the original on 9 February 2023. Retrieved 9 February 2023.
  21. 1 2 "EC approval of Rinvoq in Crohn's disease". www.thepharmaletter.com. Archived from the original on 21 April 2023. Retrieved 21 April 2023.
  22. 1 2 "Stock Market Insights". Seeking Alpha. 17 April 2023. Archived from the original on 21 April 2023. Retrieved 21 April 2023.
  23. ↑ "AbbVie Announces European Commission Approval of Rinvoq (upadacitinib) for the Treatment of Moderately to Severely Active Crohn's Disease". Yahoo Finance. 17 April 2023. Archived from the original on 21 April 2023. Retrieved 21 April 2023.
  24. 1 2 3 4 5 6 7 8 "FDA approves first oral treatment for moderately to severely active Crohn's disease". U.S. Food and Drug Administration (FDA). 18 May 2023. Archived from the original on 28 May 2023. Retrieved 2 June 2023.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  25. ↑ "U.S. FDA Approves Rinvoq (upadacitinib) as a Once-Daily Pill for Moderately to Severely Active Crohn's Disease in Adults" (Press release). AbbVie. 18 May 2023. Archived from the original on 26 May 2023. Retrieved 2 June 2023– via PR Newswire.
  26. ↑ "Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death". U.S. Food and Drug Administration (FDA). 2 September 2021. Archived from the original on 28 October 2022. Retrieved 28 October 2022.
  27. ↑ "FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions". U.S. Food and Drug Administration (FDA). 6 December 2021. Archived from the original on 28 October 2022. Retrieved 28 October 2022.
  28. 1 2 3 4 5 Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. 2020. Rinvoq 15 mg Retardtabletten.
  29. ↑ Fleischmann R (May 2012). "Novel small-molecular therapeutics for rheumatoid arthritis". Current Opinion in Rheumatology. 24 (3): 335–41. doi:10.1097/BOR.0b013e32835190ef. PMID   22357358. S2CID   826984.
  30. ↑ Riese RJ, Krishnaswami S, Kremer J (August 2010). "Inhibition of JAK kinases in participants with rheumatoid arthritis: scientific rationale and clinical outcomes". Best Practice & Research. Clinical Rheumatology. 24 (4): 513–26. doi:10.1016/j.berh.2010.02.003. PMID   20732649.
  31. ↑ "Characterization of ABT-494, a Second Generation Jak1 Selective Inhibitor". ACR Meeting Abstracts. Archived from the original on 8 December 2017. Retrieved 21 May 2017.
  32. ↑ "AbbVie Announces European Commission Approval of Rinvoq (upadacitinib) for the Treatment of Moderately to Severely Active Crohn's Disease". Yahoo Finance. 17 April 2023. Archived from the original on 21 April 2023. Retrieved 21 April 2023.
  33. ↑ "AbbVie Receives European Commission Approval for Crohn's Disease Therapeutic". PharmTech. 18 April 2023. Archived from the original on 21 April 2023. Retrieved 21 April 2023.
  34. ↑ Mohamed MF, Jungerwirth S, Asatryan A, Jiang P, Othman AA (October 2017). "Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib". British Journal of Clinical Pharmacology. 83 (10): 2242–2248. doi:10.1111/bcp.13329. PMC   5595971 . PMID   28503781.
  35. ↑ Kremer JM, Emery P, Camp HS, Friedman A, Wang L, Othman AA, et al. (December 2016). "A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy". Arthritis & Rheumatology. 68 (12): 2867–2877. doi:10.1002/art.39801. PMC   5132116 . PMID   27389975.
  36. ↑ Genovese MC, Smolen JS, Weinblatt ME, Burmester GR, Meerwein S, Camp HS, et al. (December 2016). "Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate". Arthritis & Rheumatology. 68 (12): 2857–2866. doi:10.1002/art.39808. PMC   5132065 . PMID   27390150.
  37. ↑ "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy - Full Text View - ClinicalTrials.gov". Archived from the original on 8 September 2017. Retrieved 22 May 2017.
  38. ↑ "AbbVie Announces Positive Phase 2 Study Results for Upadacitinib (ABT-494), an Investigational JAK1-Selective Inhibitor, in Crohn's Disease". Archived from the original on 17 February 2018. Retrieved 22 May 2017.
  39. ↑ "Phase 3 upadacitinib trials". Archived from the original on 27 August 2021. Retrieved 22 May 2017.
  40. ↑ Fleischmann R, Pangan AL, Song IH, Mysler E, Bessette L, Peterfy C, et al. (November 2019). "Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial". Arthritis Rheumatol. 71 (11): 1788–1800. doi:10.1002/art.41032. PMID   31287230. S2CID   195843803.
  41. ↑ Rubbert-Roth A, Enejosa J, Pangan AL, Haraoui B, Rischmueller M, Khan N, et al. (October 2020). "Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis". The New England Journal of Medicine. 383 (16): 1511–1521. doi: 10.1056/NEJMoa2008250 . PMID   33053283. S2CID   222420294.
  42. ↑ "A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs". Clinicaltrials.gov. 29 July 2021. Archived from the original on 17 April 2021. Retrieved 24 October 2020.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.